US 11,737,973 B2
Microneedle percutaneous patch containing donepezil
Tae Hyung Kim, Gyeonggi-do (KR); Booyong Lee, Seoul (KR); Jung Dong Kim, Seoul (KR); Do Hyeon Jeong, Seoul (KR); Dongchul Shin, Gyeonggi-do (KR); Yongyoun Hwang, Gyeonggi-do (KR); Yun-Sun Nam, Gyeonggi-do (KR); Joo Han Lee, Gyeonggi-do (KR); and Eun Jin An, Seoul (KR)
Assigned to Raphas Co., Ltd., Seoul (KR)
Appl. No. 16/614,527
Filed by RAPHAS CO., LTD., Seoul (KR)
PCT Filed May 16, 2018, PCT No. PCT/KR2018/005614
§ 371(c)(1), (2) Date Nov. 18, 2019,
PCT Pub. No. WO2018/212592, PCT Pub. Date Nov. 22, 2018.
Claims priority of application No. 10-2017-0062465 (KR), filed on May 19, 2017.
Prior Publication US 2020/0179272 A1, Jun. 11, 2020
Int. Cl. A61M 37/00 (2006.01); A61K 9/00 (2006.01); A61K 31/445 (2006.01); A61K 47/36 (2006.01)
CPC A61K 9/0021 (2013.01) [A61K 31/445 (2013.01); A61K 47/36 (2013.01); A61M 37/0015 (2013.01); A61M 2037/0023 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A soluble microneedle comprising a homogeneous composition of donepezil or a pharmaceutically acceptable salt thereof and hyaluronic acid or a pharmaceutically acceptable salt thereof,
wherein a weight ratio of the donepezil or the pharmaceutically acceptable salt thereof and the hyaluronic acid or a pharmaceutically acceptable salt thereof,
is 1:1.5 to 1:2.05;
wherein the content of the donepezil or the pharmaceutically acceptable salt thereof is 43 wt % or less of the total weight of the composition.